Table 5.
Survival analysis
|
|
|
Dead, N = 34
|
Median (95%CI)of the EstimatedSurvival Time
|
Log rank (Mantel-Cox)
|
P
value
|
| Gender | Female (%) | 9 (26.5) | 315.0 (134.4- 495.6) | 0.094 | 0.8 |
| Male (%) | 25 (73.5) | 441.0 (329.7- 552.3) | |||
| Smoker | No (%) | 29 (85.3) | 395.0 (299.9- 490.1) | 1.595 | 0.2 |
| Yes (%) | 5 (14.7) | 581.0 (336.4- 825.6) | |||
| DM | No (%) | 27 (79.4) | 413.0 (341.7- 484.3) | 0.259 | 0.6 |
| Yes (%) | 7 (20.6) | 429.0 (257.4- 600.6) | |||
| BCLC stages | Early (%) | 12 (35.3) | 532.0 (401.2- 662.8) | 5.594 | 0.05a |
| Intermediate (%) | 14 (41.2) | 393.0 (225.7- 560.3) | |||
| Late (%) | 8 (23.5) | 284.0 (196.6- 371.4) | |||
| Performance status | 0 (%) | 21 (61.8) | 395.0 (314.6 - 475.4) | 1.188 | 0.6 |
| 1 (%) | 12 (35.3) | 516.0 (404.0- 628.0) | |||
| 2 (%) | 1 (2.9) | 278.0 (278.0- 278.0) | |||
| 3 | 0 (0.0) | - | |||
| Child score | A (%) | 26 (76.5) | 429.0 (316.6- 541.4) | 0.574 | 0.8 |
| B (%) | 7 (20.6) | 375.0 (241.9- 508.1) | |||
| C (%) | 1 (2.9) | 516.0 (516.0- 516.0) | |||
| Response to treatment mRECIST | Stationary | 4 (11.8%) | 284.0 (215.4- 352.6) | 2.9 | 0.4 |
| Partial response | 1 (2.9%) | 412.0 (412.0- 412.0) | |||
| Complete response | 19 (55.9%) | 456.0 (346.7- 565.3) | |||
| Progressive disease | 5 (14.7%) | 128.0 (0.0- 285.2) | |||
| miRNA-326 >1.165 | 441.0 (336.7- 545.3) | 17.1 | 0.001b | ||
| miRNA-511<2.063 | 441.0 (329.5- 552.5) | 0.626 | 0.4 | ||
| miRNA-424>2.462 | 395.0 (300.7- 489.3) | 2.707 | 0.1 |
mRECIST: Modified Response Evaluation Criteria in Solid Tumors; BCLC: Barcelona Clinic Liver Cancer; DM: Diabetes mellitus; 95%CI: 95%Confidence interval.
a
P value < 0.05 is significant.
b
P value < 0.01 is highly significant.